Literature Review of Occult Hepatitis B Infection and Hepatitis B Core Antibody-Positive Blood Donors.
- 1Academic and Continuing Education Department, National Blood Centre, Thai Red Cross Society, Bangkok, THA.
- 2Laboratory for Transfusion Safety, Banc de Sang i Teixits, Barcelona, ESP.
Abstract
Hepatitis B virus (HBV) is one of transfusion-transmissible infection that is screened routinely in blood centers by serology and/or nucleic acid testing (NAT). Serology tests for HBV include antibody to hepatitis B core antigen (anti-HBc) and hepatitis B surface antigen (HBsAg). Blood centers around the world differ in their procedures for screening for HBV in blood donors. In high-income, HBV non-endemic countries, anti-HBc, HBsAg, and pooled NAT are usually used to screen blood donors, while in HBV endemic countries, anti-HBc is not usually used because it would lead to high discard rates. Donors who test positive only for anti-HBc have a history of HBV infection but have cleared the virus, resulting in negative results for both HBsAg and NAT. Deferral policy for anti-HBc-positive-only donors is restricted only to donors with high titers of anti-HBc and low titers of the protective antibody to hepatitis B surface antigen (anti-HBs) in some countries. In HBV endemic countries that screen for HBV by HBsAg and NAT, some blood donors test positive for HBsAg but negative for NAT (NAT yield donors). These test results can be the result of window period infection or occult hepatitis B infection (OBI), defined as the presence of replication-competent HBV DNA in the liver - in the presence or absence of HBV DNA in the blood - of individuals testing negative for HBsAg assessed by currently available assays. OBI donors can transmit HBV to recipients by blood transfusion. Therefore, in HBV endemic countries, individual donation NAT (ID-NAT) should be used to screen blood donors because it is more sensitive than pooled NAT and can detect both window period infection and OBI, while anti-HBc cannot detect window period infection.
Related
- Timing of Earliest Documented Positive Hepatitis C Laboratory Result Relative to Delivery Among Pregnant Persons With Active Infection in West Virginia, 2022–2023
- Prevalence and molecular characterization of hepatitis delta virus infection among hepatitis B virus surface antigen positive students and pregnant women in N'djamena, Chad
- Hepatitis B Immunoprophylaxis rarely prevents molecularly evident subclinical HBV infection in children born to HBsAg-positive mothers
- Hepatitis A Virus (HAV) Recurrence and De Novo Hepatitis A Acquired at Time of Liver Transplantation: Comparison of Graft HAV Infection and Viral Kinetics
- Mass Cytometry Reveals Cell Type-specific Immune Remodeling in Placentas of Women with Chronic Hepatitis B Infection
BibTeX
@article{thongthaisin2026literature,
title = {{Literature Review of Occult Hepatitis B Infection and Hepatitis B Core Antibody-Positive Blood Donors.}},
author = {Aphisit Thongthaisin and Silvia Sauleda},
journal = {Cureus},
year = {2026},
month = sep,
doi = {10.7759/cureus.116625},
url = {https://europepmc.org/article/MED/42909874},
note = {CC BY},
}
RIS
TY - JOUR
TI - Literature Review of Occult Hepatitis B Infection and Hepatitis B Core Antibody-Positive Blood Donors.
AU - Aphisit Thongthaisin
AU - Silvia Sauleda
PY - 2026
DA - 2026/09/21
JO - Cureus
DO - 10.7759/cureus.116625
UR - https://europepmc.org/article/MED/42909874
AB - Hepatitis B virus (HBV) is one of transfusion-transmissible infection that is screened routinely in blood centers by serology and/or nucleic acid testing (NAT). Serology tests for HBV include antibody to hepatitis B core antigen (anti-HBc) and hepatitis B surface antigen (HBsAg). Blood centers around the world differ in their procedures for screening for HBV in blood donors. In high-income, HBV non-endemic countries, anti-HBc, HBsAg, and pooled NAT are usually used to screen blood donors, while in HBV endemic countries, anti-HBc is not usually used because it would lead to high discard rates. Donors who test positive only for anti-HBc have a history of HBV infection but have cleared the virus, resulting in negative results for both HBsAg and NAT. Deferral policy for anti-HBc-positive-only donors is restricted only to donors with high titers of anti-HBc and low titers of the protective antibody to hepatitis B surface antigen (anti-HBs) in some countries. In HBV endemic countries that screen for HBV by HBsAg and NAT, some blood donors test positive for HBsAg but negative for NAT (NAT yield donors). These test results can be the result of window period infection or occult hepatitis B infection (OBI), defined as the presence of replication-competent HBV DNA in the liver - in the presence or absence of HBV DNA in the blood - of individuals testing negative for HBsAg assessed by currently available assays. OBI donors can transmit HBV to recipients by blood transfusion. Therefore, in HBV endemic countries, individual donation NAT (ID-NAT) should be used to screen blood donors because it is more sensitive than pooled NAT and can detect both window period infection and OBI, while anti-HBc cannot detect window period infection.
SN - 2168-8184
ER -